Until the feasibility of sentinel lymph node (SLN) biopsy and its reliability as a staging procedure were established in the early 1990s, it was the policy of many large melanoma treatment centers worldwide to perform an elective lymph node dissection (ELND) of the relevant regional node field for patients with cutaneous melanomas more than 1.5 mm thick. 1 Because only about 20% of this group of patients had nodal involvement in regional node fields, the remaining 80% of patients undergoing ELNDs were placed unnecessarily at risk of anesthetic complications and surgical morbidity (including acute wound problems, nerve injury and chronic lymphedema). 2, 3 It is now well established that SLN biopsy is a minimally invasive procedure that accurately indicates the regional node status of patients with melanoma. Indeed, it has proved to be the single most important prognostic factor for patients with early-stage melanoma. [3] [4] [5] [6] Based on the finding of metastatic cells in SLNs, completion lymph node dissections (CLNDs) can now be performed only in selected patients with melanoma, while all other patients are spared this major and potentially morbid surgical procedure. However, among patients with positive SLNs, further nodal involvement in CLND specimens is identified in only 8% to 30% of cases. [7] [8] [9] If the pathologic features of patients' positive SLNs could be used to predict who would not have further nodal involvement in a CLND specimen, these individuals also could be spared such major surgery and its inherent risks. Therefore, this study was performed with the aim of determining whether micromorphometric features of positive SLNs from patients with melanoma are useful for predicting which patients will and will not have further nodal involvement in CLND specimens.
The aim of the present study was to determine whether micromorphometric features of positive sentinel lymph nodes (SLNs) from patients with melanoma are useful for predicting further nodal involvement in completion lymph node dissection (CLND) specimens. Of 986 patients with melanoma undergoing SLN biopsy between March 1992 and February 2001, 175 (17.7%) had at least 1 positive SLN and 140 had subsequent CLND specimens available for review. Further nodal involvement in CLND specimens was present in 24 (17.1%) of 140 patients. Of 8 micromorphometric features of the SLNs that were assessed, the presence of metastases in CLND specimens was correlated significantly with a tumor penetrative depth (maximum distance of melanoma cells from the inner margin of the SLN capsule) of more than 2 mm (P < .05), a deposit size of more than 10 mm 2 (P < .01), the presence of melanoma cells in perinodal lymphatic vessels (P < .01), and the effacement of nodal architecture by metastatic melanoma cells (P < .05). Our results indicate that some morphologic features of melanoma metastases in SLNs predict the likelihood of further nodal involvement in CLND specimens.
Until the feasibility of sentinel lymph node (SLN) biopsy and its reliability as a staging procedure were established in the early 1990s, it was the policy of many large melanoma treatment centers worldwide to perform an elective lymph node dissection (ELND) of the relevant regional node field for patients with cutaneous melanomas more than 1.5 mm thick. 1 Because only about 20% of this group of patients had nodal involvement in regional node fields, the remaining 80% of patients undergoing ELNDs were placed unnecessarily at risk of anesthetic complications and surgical morbidity (including acute wound problems, nerve injury and chronic lymphedema). 2, 3 It is now well established that SLN biopsy is a minimally invasive procedure that accurately indicates the regional node status of patients with melanoma. Indeed, it has proved to be the single most important prognostic factor for patients with early-stage melanoma. [3] [4] [5] [6] Based on the finding of metastatic cells in SLNs, completion lymph node dissections (CLNDs) can now be performed only in selected patients with melanoma, while all other patients are spared this major and potentially morbid surgical procedure. However, among patients with positive SLNs, further nodal involvement in CLND specimens is identified in only 8% to 30% of cases. [7] [8] [9] If the pathologic features of patients' positive SLNs could be used to predict who would not have further nodal involvement in a CLND specimen, these individuals also could be spared such major surgery and its inherent risks. Therefore, this study was performed with the aim of determining whether micromorphometric features of positive SLNs from patients with melanoma are useful for predicting which patients will and will not have further nodal involvement in CLND specimens.
Materials and Methods
The database of the Sydney Melanoma Unit, Royal Prince Alfred Hospital, Sydney, Australia, was used to identify patients who had undergone SLN biopsy. Archival pathology slides and tissue blocks were retrieved from the Department of Anatomical Pathology, Royal Prince Alfred Hospital. Between March 1992 and February 2001, 986 patients with a single primary cutaneous melanoma underwent successful SLN biopsy. An SLN biopsy procedure was offered, in the context of a clinical trial protocol, if a patient had no clinical signs of metastasis and if the primary melanoma had a Breslow thickness of at least 1.0 mm or, if less than 1.0 mm, had invaded the reticular dermis (Clark level IV).
For pathologic evaluation, all SLNs were fixed in 10% buffered formalin for 24 hours, then cut along their longitudinal axis in 3-mm-thick slices and embedded in entirety in paraffin blocks following tissue processing. Four sequential 5-µm-thick tissue sections were cut from each block and stained with H&E (on sections 1 and 4) and immunohistochemically for S-100 and HMB-45 (on sections 2 and 3 respectively).
Metastatic melanoma cells were identified in at least 1 SLN in 175 patients (17.7% of total cases). All but 8 patients underwent subsequent CLND. The reasons for not performing CLND in the 8 cases included patient refusal (3 patients), medical contraindication (4 patients), and death from an unrelated cause before a CLND was undertaken (1 patient). Of the remaining 167 cases, all the slides from the positive SLNs and the CLND specimens were available for review in 140 cases. Within this final study group of 140 cases, the median number of SLNs removed per patient was 2 (range, [1] [2] [3] [4] [5] [6] [7] [8] , and the median number of nodes removed per CLND was 14 (range, 2-41). These values are similar to those for the entire population of 167 patients who had a positive SLN, suggesting that there was no selection bias in the study group. The positive SLN biopsy specimens were obtained from the following sites: axilla, 56 (40.0%); groin, 66 (47.1%); head and neck, 13 (9.3%); other sites, 5 (3.6%).
A number of micromorphometric features of each positive SLN were assessed by 2 independent observers (R.A.S. and L.-X.L.L.) ❚Table 1❚. The features included the number of positive SLNs, number of metastatic foci, maximum diameter and size (area in square millimeters as measured microscopically in tissue sections) of the largest metastasis, percentage of the nodal area involved, tumor penetrative depth of metastasis (maximum distance of melanoma cells from the inner margin of the SLN capsule) ❚Image 1A❚, pattern of nodal involvement, presence and extent of extranodal spread, and presence of tumor cells within perinodal lymphatic vessels. Measurements of tumor deposit diameter, size, and centripetal thickness were made using an ocular micrometer. The size (area in square millimeters) of the largest metastasis and the percentage of the nodal area it involved were calculated from its shape and dimensions as measured microscopically in 2 dimensions in the tissue sections. All positive SLNs from each patient were assessed, and if more than 1 SLN was involved in an individual patient, each morphometric feature was assessed in each positive SLN and the greatest figure recorded.
All cases were evaluated without knowledge of regional nodal involvement. When there were discrepant results between the 2 observers, a consensus result was obtained by jointly reevaluating the cases.
All lymph nodes in CLND specimens were submitted in entirety for histopathologic examination. Whole nodes were embedded in paraffin and sliced when the nodes were more than 3 mm in diameter. H&E-stained sections were examined microscopically for the presence of melanoma metastases.
The independent t test and the χ 2 test were used to detect significant associations between the micromorphometric 
Results
Of the 140 patients with positive SLNs, further nodal involvement in CLND specimens (ie, non-SLN metastasis) was detected in 24 patients (17.1%). The median and mean numbers of positive SLNs per patient detected by pathologic examination were 1 and 1.26, respectively (range, 1-4). The median and mean numbers of positive non-SLN nodes in CLND specimens per patient were 1 and 2.5, respectively (range, 1-16). In the 24 patients with positive non-SLNs in CLND specimens, the median and mean Breslow thicknesses of their primary melanomas were 2.8 and 3.2 mm, respectively (range, 1.45-8 mm). These values are similar to the median and mean values of 2.5 and 3.4 mm, respectively (range, 0.52-15 mm) for the 116 patients with negative CLND specimens.
The median, mean, and range for each of the studied quantitative features of positive SLNs and their correlation with the presence or absence of positive non-SLNs in corresponding CLND specimens are given in ❚Table 2❚. There were no significant differences in the mean values of these variables between patients with and without positive non-SLNs in their CLND specimens by the independent t test (P > .05). However, the χ 2 test revealed that the presence of non-SLN metastases in CLND specimens was correlated significantly with tumor penetrative depth of more than 2 mm (P < .05) (Image 1A), deposit size of more than 10 mm 2 (P < .01) ❚Image 1B❚, the presence of melanoma cells in perinodal lymphatics (P < .01) ❚Image 1C❚, and effacement of nodal architecture by metastatic melanoma cells (P < .05) (Image 1B) ❚Table 3❚. None of the other micromorphometric features assessed was correlated significantly with the presence of non-SLN metastases in CLND specimens. These features included the number of positive SLNs, the number of metastatic foci, the maximum diameter of the largest tumor deposit, the location of tumor deposits within the node, and the presence and extent of extracapsular spread. A tumor penetrative depth of more than 2 mm predicted positive CLND involvement in 28% of cases (12/43), and a tumor penetrative depth of 2 mm or less predicted negative CLND involvement in 88% of cases (85/97) ( Table 3) . The positive and negative predictive values for the coevaluation of a number of the 4 micromorphometric features of SLNs that were associated significantly with the presence of non-SLN metastases in CLND specimens were also calculated. Non-SLN involvement in the CLND specimen was present in 6 (50%) of 12 cases in which the 3 most frequently occurring of the 4 features (tumor penetrative depth of >2 mm, deposit size of >10 mm 2 , and effacement of nodal architecture) were present in the SLNs (P < .01). All of these 3 features were absent in the SLNs of 94 patients, and 82 (87%) of them had no non-SLN involvement (P < .05). There was only 1 case in which all 4 features (all 3 aforementioned features plus the presence of perinodal lymphatic vessel involvement by tumor) were present in the SLN, and this case was associated with the presence of non-SLN metastasis in the CLND specimen (P > .05). All 4 features were absent in the SLNs of 91 patients, and 81 (89%) of them did not have non-SLN involvement in the CLND specimen (P < .01).
Discussion
Melanomas commonly metastasize via lymphatics to regional lymph nodes, and before the era of SLN biopsy, ELND often was performed in patients with advanced primary lesions with the objective of removing early metastatic disease. 1, 10 However, clinical trials failed to demonstrate convincing improvement in overall survival, [11] [12] [13] and there was concern about the associated morbidity, particularly the troublesome chronic lymphedema that regularly resulted from ELND of the groin. 2 Routine ELND, therefore, was abandoned as a treatment option in most centers.
It is now well documented that the SLN biopsy technique provides accurate information about the regional node status of patients with melanoma. 3, 4, [14] [15] [16] A patient whose SLN is negative can be regarded as being free of melanoma involvement in the entire regional node field and, thus, spared an invasive CLND procedure. 3, 8, 15 Because only a proportion of patients with positive SLNs have further metastatic disease detected in non-SLNs when CLND is performed, [7] [8] [9] identifying factors that might predict or influence the spread of melanoma cells to non-SLNs would be useful. Starz et al 8 recently reported that micromorphometric features of SLNs, in particular centripetal thickness (defined as the maximum distance of melanoma cells from the inner margin of the SLN capsule and equivalent to our measurement of tumor penetrative depth), might be useful in predicting further nodal involvement in CLND specimens. Furthermore, they suggested that centripetal thickness of melanoma deposits in SLNs also might provide additional prognostic information complementing the TNM staging system for primary cutaneous melanoma. 8 We have chosen the term tumor penetrative depth to describe the maximum distance of melanoma cells from the inner margin of the SLN rather than centripetal thickness used by Starz et al. 8 While both terms apply to the same measurement, we believe tumor penetrative depth is a more accurate description of this feature. Centripetal thickness implies that there is continuous tumor from the inner margin of the SLN capsule, when in fact the measurement being recorded is the maximal depth at which tumor cells are located within the SLN. In some positive SLNs, we identified single deposits of tumor within the parenchyma of the node, not involving the peripheral sinus or the immediately subjacent nodal tissue ❚Image 2❚. In such cases, use of the term centripetal thickness to describe the distance of melanoma cells from the inner margin of the SLN is clearly inappropriate.
The concept of orderly progression of lymph node metastases implies that the risk of spread of tumor from SLNs to non-SLNs depends on the extent of SLN involvement. That is, the risk of spread to non-SLNs is likely to be 
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❚Image 2❚ Metastatic melanoma involving the interfollicular parenchymal region of a sentinel lymph node (A, H&E, original magnification ×100; B, immunohistochemical stain for HMB45, original magnification ×100).
greater when there are macrometastases of thousands or tens of thousands of tumor cells within the SLN compared with the risk when only a few tumor cells are present. Consistent with this concept and the report by Starz and colleagues, 8 our study found that greater penetrative depth of tumor deposits within SLNs, greater size of tumor deposits, effacement of nodal architecture, and the presence of perinodal lymphatic deposits correlated significantly with the more frequent detection of non-SLN involvement in CLND specimens. However, Starz et al 8 found non-SLN involvement in CLND specimens in 9 (60%) of 15 patients with an SLN centripetal thickness of more than 1 mm ❚Table 4❚. In contrast with their results, in our considerably larger study, we found positive non-SLN involvement in CLND specimens in only 13 (19%) of 69 patients with a tumor penetrative depth of more than 1 mm (P > .05). However, we found that an SLN tumor penetrative depth of more than 2 mm was associated significantly with an increased risk of non-SLN metastasis and that a tumor penetrative depth of 2 mm or less predicted absence of further nodal involvement in CLND specimens in 88% of cases (85/97) ( Table 3) . It is interesting that our study also revealed that a greater size of tumor deposits, effacement of nodal architecture, and presence of perinodal lymphatic involvement predicted a significant increase in the risk of developing non-SLN metastases. We did not find that the presence or extent of extracapsular spread were significant in predicting further nodal involvement; however, the small number of cases that displayed this feature might account for this finding. Determining whether the presence of extracapsular tumor spread in SLNs is a risk factor for the development of locoregional recurrence and distant metastasis also would require more cases.
The results of our study suggest that it might be more useful to select which patients should undergo CLND on the basis of a combination of morphologic features of their positive SLNs rather than solely on the basis of the tumor penetrative depth. When 3 of these 4 features (SLN tumor penetrative depth of >2 mm, deposit size of >10 mm 2 , and effacement of nodal architecture) were present in an SLN, the positive predictive value of non-SLN involvement in the CLND specimen was 50% (6/12) compared with a positive predictive value of 28% (12/43) for evaluation based only on the presence of an SLN tumor penetrative depth of more than 2 mm. The fourth SLN feature (tumor cells within perinodal lymphatic vessels) was observed infrequently, which probably limits its usefulness as a predictor of non-SLN involvement. The presence of all 4 features within an SLN was identified only in 1 case in our series and, therefore, was not statistically significant for predicting the presence of non-SLN involvement. The observation that the negative predictive value of the absence of all 4 micromorphometric features (89% [81/91]) was only slightly greater than that of the tumor penetrative depth of more than 2 mm (88% [85/97]) probably reflects the codependence of these variables (particularly tumor penetrative depth, deposit size, and effacement of nodal architecture).
Although we attempted to measure tumor penetrative depth in SLNs using exactly the same definition and method used for centripetal thickness by Starz et al, 8 differences in the interpretation of how the measurement was determined might account for the differences in our results. In many cases we found it difficult to measure the tumor penetrative depth. For example, in some cases, single deposits of tumor were present within the parenchyma of the node, not involving the peripheral sinus (Image 2). Although most of these deposits were very small, the tumor penetrative depth in some cases was more than 1 mm. In other cases, it appeared that metastases had been deposited in sinuses of the intranodal fibrous trabecular septa that extend into the medulla of the lymph node from the peripheral capsule rather than in the peripheral subcapsular sinus. Occasionally deposits of melanoma cells were scattered throughout the SLN. In some cases, the tumor deposits extended beyond the center of the lymph node, making it difficult to determine which edge of the lymph node capsule should be used to measure the tumor penetrative depth (particularly when the medulla of the node was not obvious). Similar difficulties were encountered when there were deposits near the hilum of the node, where the capsule was lacking, or in regions where the node had a lobulated outline. Further studies that more rigorously define the measurement of tumor penetrative depth might strengthen its predictive power. In addition, assessment of its reproducibility among pathologists will be necessary.
Apart from differences in interpretation, there were other differences between the 2 studies that might have influenced the results. For example, the method of slicing the lymph nodes macroscopically before tissue processing and the sectioning and staining protocols used to assess the tumor-harboring status of SLNs were not the same in the 2 studies. In contrast with the routine use of immunohistochemical stains for S-100 and HMB-45 in the assessment of all SLNs, immunohistochemical analysis was not used routinely to assess nodes in CLND specimens in our study. Thus, the method of our study differed from that of Starz and colleagues, 8 who used immunostains for S-100 routinely on all nodes in CLND specimens. It is not known how many, if any, of the metastases within non-SLNs in their study were detected only by immunohistochemical analysis. It is possible that the use of more detailed pathologic analysis of CLND specimens with multiple sections assisted by immunohistochemical analysis might increase the detection rate of melanoma metastases in these specimens. However, in another study that we performed, no difference in the detection rate of micrometastatic disease in non-SLNs from CLND specimens was observed when H&E-stained sections were examined compared with sections stained immunohistochemically for S-100 and HMB-45. 17 This information supports our view that differences in the immunohistochemical protocols used in the 2 studies are unlikely to have had a major impact on our results. A number of other studies that have attempted to identify factors predictive of occult non-SLN metastases after a positive SLN has been removed also have yielded conflicting results. Salti and Das Gupta 18 recently reported that only the number of positive SLNs predicted the status of non-SLNs but not other characteristics (SLN metastases, number of draining nodal basins, age, sex, tumor thickness, Clark level, ulceration, number of mitoses per square millimeter, histologic subtype, or location of the primary tumor). Reeves and colleagues 19 found that primary tumor characteristics (thickness, ulceration, and absence of regression) and SLN tumor characteristics (size of >2 mm, nonsubcapsular location) correlated with the presence of non-SLN metastases in univariate analysis. However, in multivariate analysis, they found that only the size-ulceration score (derived by assigning 1 point for primary tumor ulceration and 1 point for SLN tumor size of >2 mm) was a statistically independent predictor of non-SLN status. 19 We found that the median and mean thicknesses of the primary cutaneous tumors were similar for patients with and patients without non-SLN metastases in CLND specimens. As previously reported by others, 20 this suggests that there is no correlation between the thickness of primary cutaneous melanomas and the presence or absence of non-SLN metastases in specimens from CLNDs performed following detection of a positive SLN. It seems likely that the development of non-SLN metastases might be related more to the transportation and growth of metastatic cells within SLNs, once metastatic cells have invaded the SLNs. In some cases, metastatic melanoma cells might remain in the subcapsular sinus of an SLN for a prolonged period, while in other cases, melanoma cells might grow rapidly (resulting in a greater tumor penetrative depth) and spread to other nodes. Although the SLN theory contends that there is no direct spread from the primary tumor to non-SLNs, on occasion, such spread might occur. For example, afferent lymphatics draining to an SLN might be blocked by tumor and cause spread directly to non-SLNs in the absence of SLN metastasis.
The micromorphometric patterns observed in SLNs are likely to be simply a reflection of underlying biologic events, influenced in turn by the microanatomy of individual lymph nodes, the expression of certain chemokine receptors and adhesion molecules on tumor cells, and the function of the patient's immune system. It is these biologic events, rather than the micromorphometric patterns per se, that are likely to influence the spread of melanoma cells from SLNs to nonSLNs. Recent studies have suggested that the microenvironment in an SLN, which leads to and is associated with micrometastasis, is different from that in a non-SLN. 21, 22 The process probably is mediated immunologically, because dramatic and profound immunosuppression of the SLN as a result of its direct exposure to immunosuppressive factors from the primary tumor has been demonstrated. 23 It is postulated that once metastases have implanted successfully in the SLN and begun to grow, they in turn produce more (and possibly different) immunosuppressive factors that eventually lead to the spread of micrometastatic disease to other lymph nodes and, ultimately, to systemic sites. Further studies that investigate the biology of melanoma cells and their interaction with the SLN host environment might provide a greater understanding of the mechanisms by which melanoma metastases spread from SLNs to non-SLNs.
The results of this study suggest that some morphometric features of melanoma deposits in SLNs correlate significantly with the likelihood of further nodal involvement in CLND specimens.
